<--- Back to Details
First PageDocument Content
Cancer / Clinical medicine / Medicine / Tyrosine kinase receptors / Bladder cancer / RTT / Anatomical pathology / Transitional cell carcinoma / Fibroblast growth factor receptor 3 / Metastasis / Fibroblast growth factor receptor 1 / Carcinogenesis
Cancer
Clinical medicine
Medicine
Tyrosine kinase receptors
Bladder cancer
RTT
Anatomical pathology
Transitional cell carcinoma
Fibroblast growth factor receptor 3
Metastasis
Fibroblast growth factor receptor 1
Carcinogenesis

Cancer Medicine Open Access ORIGINAL RESEARCH

Add to Reading List

Source URL: michorlab.dfci.harvard.edu

Download Document from Source Website

File Size: 1,45 MB

Share Document on Facebook

Similar Documents

#4503 A Small Molecule Glycomimetic Antagonist of E-selectin (GMIPrevents Pancreatic Tumor Metastasis and Offers Improved Efficacy of Chemotherapy Maria M. Steele1, BS, Prakash Radhakrishnan1, PhD, John L. Magnani

DocID: 1vkKU - View Document

Quantitative image-based phenotypes for cancer metastasis systems biology Joel S. Bader, Ph.D. Professor, Biomedical Engineering Johns Hopkins University

DocID: 1vd8y - View Document

A  small  molecule  glycomime.c  antagonist   of  E-­‐selec.n  and  CXCR4  (GMI-­‐1359)   delays  pancrea.c  tumor  metastasis  and   significantly  alters  the

DocID: 1uubq - View Document

Why we focus on Metastasis & Invasion Around 90% of cancer deaths are attributable to invasion and metastasis. Metastasis is the spread of disease from one organ or part to another not directly connected with the primary

DocID: 1sjoH - View Document

Nota de Prensa LA FDA APRUEBA DENOSUMAB PARA LA PREVENCIÓN DE EVENTOS ESQUELÉTICOS EN PACIENTES CON METÁSTASIS ÓSEAS DE TUMORES SÓLIDOS BARCELONA. (nov. 19, 2010) – La FDA ha aprobado denosumab, el primer y

DocID: 1s5nh - View Document